Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 126 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Follow-Up Questions
Qui est le CEO de Edgewise Therapeutics Inc ?
Dr. Kevin Koch est le President de Edgewise Therapeutics Inc, il a rejoint l'entreprise depuis 2017.
Quelle est la performance du prix de l'action EWTX ?
Le prix actuel de EWTX est de $15.06, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Edgewise Therapeutics Inc ?
Edgewise Therapeutics Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Edgewise Therapeutics Inc ?
La capitalisation boursière actuelle de Edgewise Therapeutics Inc est de $1.5B
Est-ce que Edgewise Therapeutics Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 15 analystes ont établi des notations d'analystes pour Edgewise Therapeutics Inc, y compris 6 achat fort, 9 achat, 3 maintien, 0 vente et 6 vente forte
